SPECC1L is altered in 0.02% of all cancers with sarcoma, NOS, breast invasive lobular carcinoma, inflammatory myofibroblastic tumor, primitive neuroectodermal tumor, and sarcomatoid renal cell carcinoma having the greatest prevalence of alterations .
The most common alterations in SPECC1L are SPECC1L-ADORA2A-ALK Fusion (0.01%) and SPECC1L-ADORA2A-RAF1 Fusion (0.01%) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.